Key takeaways:

Vaccine could improve survival for patients with pancreatic and colorectal cancers.

Vaccine targets mutant KRAS and could be applicable to other cancer types.

A novel, off-the-shelf vaccine that targets KRAS mutations could dramatically improve the “dismal” outlook patients with pancreatic cancer face after relapse.

Final results of a phase 1 investigation showed individuals who developed strong T-cell responses to mutant KRAS from the vaccine — ELI-002 2P (Elicio Therapeutics) — did not reach a median RFS or OS after nearly 20 months of follow-up.

The vaccine could have an impact on other tumors with KRAS mutations, too, including colorectal cancer.

“We’re really excited about what we see so far,” Zev A. Wainberg, MD, professor of medicine and co-director of

See Full Page